191 results
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
of office, will not become a party to (1) any agreement, arrangement or understanding with, and has not given and will not give any commitment … Commitment”) or (2) any Voting Commitment that could limit or interfere with such proposed nominee’s ability to comply, if elected as a Director
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
% to 1.50% per annum for base rate loans. The revolving credit facility is subject to a commitment fee payable on the unused revolving credit facility
8-K
EX-10.1
2vnor 7xvj1
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
425
EX-99.1
raxthbcr vhpm09n1g
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
oaiekus
21 Jun 22
Regulation FD Disclosure
6:19am
425
fo09kf7j
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.4
886hh208jl5
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.2
wwp4r636
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.1
72dbhzelxmcb
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
425
EX-99.2
73sz4h89no
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.2
00j378ie1 xysb
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm